ALX Oncology

Hiker having trouble climbing mountain
Biotech

ALX Oncology doubles down as lead asset fails 2 phase 2 trials

Evorpacept failed to meet the primary endpoints of two head and neck cancer trials, causing the company to scrap further attempts in the indication.
Darren Incorvaia Apr 25, 2025 2:25pm
layoffs cut staff reduction workforce

ALX lays off 30% of staff to pay for more trials of CD47 blocker

Mar 5, 2025 9:40am
photo of a paraglider in the foreground with the alps in the background

Flagship-backed biotechs name new leaders—Chutes & Ladders

Nov 15, 2024 8:30am
downturn economy markets bank negative fall down

ALX's fizzling CD47 response rate sends stock spiraling down

Aug 1, 2024 5:34am
Graphic of a number of arrows missing the bullseye on a target except for one arrow

ALX links CD47 drug to improved response rate in solid tumors

Oct 3, 2023 6:15am
chutes parachutes Turkey

Illumina nets new CEO—Chutes & Ladders

Sep 8, 2023 9:30am